TY - JOUR
T1 - The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases
AU - Schiavon, Gaia
AU - Ruggiero, Alessandro
AU - Bekers, DJ
AU - Barry, PA
AU - Sleijfer, Stefan
AU - Kloth, Jacqueline
AU - Krestin, Gabriel
AU - Schoffski, P
AU - Verweij, Jaap
AU - Mathijssen, Ron
PY - 2014
Y1 - 2014
N2 - Purpose: Tumour response assessment to therapy is crucial in oncology. We analysed the morphology of liver metastases (LM) in gastrointestinal stromal tumour (GIST) patients to determine whether uni-dimensional measurement of lesions by Response Evaluation Criteria in Solid Tumours (RECIST), accurately reflects lesion volume. Materials and methods: The volumes of LM (n = 139) from a GIST patient cohort were measured using computed tomography (CT) at baseline, 3, 6 and 12 months after commencement of imatinib therapy. Baseline measurements were obtained by two independent investigators and inter-observer agreement assessed using Bland-Altman plots. Actual lesion volumes (V-ACTUAL) were measured and compared with volumes based on the RECIST measure (V-RECIST), and with volumes based on three orthogonal measures (V-ELLIPSOID) at several time-points. Results: At baseline, the inter-observer bias for V-ACTUAL was just 1.8%. V-RECIST and V-ELLIPSOID overestimated V-ACTUAL by a mean of 35% and only 9% respectively (P < 0.0001 for both). At baseline, 44% (61/139) of LM were classified as spheroidal and 56% (78/139) as ellipsoidal. During treatment, only 42% of LM retained their original morphology. The remainder demonstrated significant changes in morphology (from spheroidal to ellipsoidal and vice versa) over time, while the RECIST measure did not reflect such changes. Conclusions: The morphology of LM in GIST is rarely spherical ( an underlying assumption for RECIST) and can change considerably during imatinib therapy. In this setting, measurements using RECIST do not reflect changes in size and morphology. Additionally, whilst V-ELLIPSOID is a more suitable surrogate for volume estimation, it is still somewhat limited by the morphology and orientation of such lesions. Studies are warranted to further explore the clinical impact of these findings. (C) 2014 Elsevier Ltd. All rights reserved.
AB - Purpose: Tumour response assessment to therapy is crucial in oncology. We analysed the morphology of liver metastases (LM) in gastrointestinal stromal tumour (GIST) patients to determine whether uni-dimensional measurement of lesions by Response Evaluation Criteria in Solid Tumours (RECIST), accurately reflects lesion volume. Materials and methods: The volumes of LM (n = 139) from a GIST patient cohort were measured using computed tomography (CT) at baseline, 3, 6 and 12 months after commencement of imatinib therapy. Baseline measurements were obtained by two independent investigators and inter-observer agreement assessed using Bland-Altman plots. Actual lesion volumes (V-ACTUAL) were measured and compared with volumes based on the RECIST measure (V-RECIST), and with volumes based on three orthogonal measures (V-ELLIPSOID) at several time-points. Results: At baseline, the inter-observer bias for V-ACTUAL was just 1.8%. V-RECIST and V-ELLIPSOID overestimated V-ACTUAL by a mean of 35% and only 9% respectively (P < 0.0001 for both). At baseline, 44% (61/139) of LM were classified as spheroidal and 56% (78/139) as ellipsoidal. During treatment, only 42% of LM retained their original morphology. The remainder demonstrated significant changes in morphology (from spheroidal to ellipsoidal and vice versa) over time, while the RECIST measure did not reflect such changes. Conclusions: The morphology of LM in GIST is rarely spherical ( an underlying assumption for RECIST) and can change considerably during imatinib therapy. In this setting, measurements using RECIST do not reflect changes in size and morphology. Additionally, whilst V-ELLIPSOID is a more suitable surrogate for volume estimation, it is still somewhat limited by the morphology and orientation of such lesions. Studies are warranted to further explore the clinical impact of these findings. (C) 2014 Elsevier Ltd. All rights reserved.
U2 - 10.1016/j.ejca.2014.01.004
DO - 10.1016/j.ejca.2014.01.004
M3 - Article
C2 - 24480402
SN - 0959-8049
VL - 50
SP - 972
EP - 980
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 5
ER -